Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017
July 26 2017 - 8:00AM
Vericel Corporation (NASDAQ:VCEL), a leading developer of
autologous expanded cell therapies for the treatment of patients
with serious diseases and conditions, today announced the following
webcast and conference call:
|
|
What: |
Vericel
Corporation Second-Quarter 2017 Earnings Call |
|
|
When: |
Wednesday,
August 9, 2017 at 8:00am (EDT) |
|
|
Where: |
http://investors.vcel.com/events.cfm |
|
|
How: |
The
conference call will be available live in the Investors section of
the Vericel website at http://investors.vcel.com/events.cfm.
Please access the site at least 15 minutes prior to the
scheduled start time in order to download the required audio
software if necessary. |
|
|
To participate in the live call by telephone, please call (877)
312-5881 and reference Vericel Corporation second-quarter 2017
investor conference call. If calling from outside the U.S., please
use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events.cfm until
August 9, 2018. A replay of the call will also be available until
11:00am (EDT) on August 13, 2017 by calling (855) 859-2056, or from
outside the U.S. (404) 537-3406. The conference ID is 54878623.
About Vericel CorporationVericel develops,
manufactures, and markets autologous expanded cell therapies for
the treatment of patients with serious diseases and
conditions. The company markets two cell therapy products in
the United States. Vericel is
marketing MACI® (autologous cultured chondrocytes on
porcine collagen membrane), an autologous cellularized scaffold
product indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Vericel is also marketing Epicel®
(cultured epidermal autografts), a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. Vericel is
developing ixmyelocel-T, an autologous multicellular therapy
intended to treat advanced heart failure due to ischemic dilated
cardiomyopathy. For more information, please visit the company's
website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of
Vericel Corporation. © 2017 Vericel Corporation. All
rights reserved.
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
David.schull@russopartnersllc.com
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
Karen.chase@russopartnersllc.com
Investor Contacts:
Chad Rubin
The Trout Group
crubin@troutgroup.com
+1 (646) 378-2947
Lee Stern
The Trout Group
lstern@troutgroup.com
+1 (646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2024 to May 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From May 2023 to May 2024